New schistosomiasis vaccine shows promise in early african trials
NCT ID NCT05762393
First seen Feb 05, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tested a new vaccine called SchistoShield® in 120 healthy adults aged 20-59 in Burkina Faso and Madagascar. The goal was to check the vaccine's safety and how well it triggers the immune system. Participants received three doses of either the vaccine or a placebo over two months, with different strengths tested. The results will help decide if the vaccine is safe enough for larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHISTOSOMIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Groupe de Recherche Action en Santé (GRAS)
Ouagadougou, Burkina Faso
-
Madagascar Institute for Vaccine Research (University of Antananarivo)
Antananarivo, Madagascar
Conditions
Explore the condition pages connected to this study.